Marinus Pharmaceuticals, Inc.

MRNS

US56854Q2003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
1.35 ^USD	+1.50%		-8.78%	-87.58%

May. 08	Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	MT
May. 08	Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for 2023

August 10, 2023 at 08:30 am EDT

Marinus Pharmaceuticals, Inc. provided revenue guidance for 2023. For the year, With the exceptional early performance of ZTALMY, the company increased revenue guidance for 2023 to a range of $17 million to $18.5 million.

Latest news about Marinus Pharmaceuticals, Inc.

Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	May. 08	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	May. 08	CI
HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	May. 07	MT
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	Apr. 17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	Apr. 16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	Apr. 16	MT
North American Morning Briefing : Powell Comments, -2-	Apr. 16	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone	Apr. 15	MT
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	Apr. 15	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency	Mar. 07	MT
UK Approves Marinus Pharmaceuticals' Ztalmy for Rare Genetic Disorder	Mar. 07	MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	Mar. 06	MT
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket	Mar. 06	MT
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours	Mar. 05	MT
Transcript : Marinus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M	Mar. 05	MT
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024	Mar. 05	CI
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	Jan. 22	MT
Marinus Pharmaceuticals Raises 2023 Product Revenue Expectation	Jan. 04	MT
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating	Jan. 03	MT

Chart Marinus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Sector

Pharmaceuticals

Calendar

2024-05-15 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Marinus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.33 USD

Average target price

6.667 USD

Spread / Average Target

+401.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MARINUS PHARMACEUTICALS, INC.	-87.58%	73.06M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals